Abstract:BackgroundCardiovascular diseases (CVDs) are the leading cause of death worldwide, causing over 17 million deaths each year. According to the World Health Organization (WHO), 85% of CVD deaths are due to heart disease and strokes, and over 75% occur in low- and middle-income countries (LMICs). Early detection and treatment are key to preventing consequences of CVD. Point-of-care testing (POCT) devices require minimal laboratory infrastructure and can be used to screen hard-to-reach populations for CVD risk. These devices are increasingly used in traditional care settings including hospitals and primary healthcare, and in non-traditional settings such as pharmacies. Although POCT devices offer fast and convenient testing, the analytical performance of these devices must produce accurate and reliable results, and have technical suitability for use. Several POCT devices for total cholesterol (TC) and other blood lipids are commercially available, however, the operational and analytical performance of these devices is not fully known.MethodsEight POCT devices for blood lipids were used in this study. For the technical assessment, a checklist was developed and applied, outlining the operational functionality and environmental conditions of the devices. Some relevant technical parameters in this checklist included requirements for temperature/humidity and power/voltage, storage conditions, and assay/test time. The analytical performance was assessed for parameters, such as accuracy and imprecision, using paired whole blood and serum donor samples for TC. In addition, these analytical parameters were assessed for serum High Density Lipoprotein-cholesterol (HDL-c) and Low Density Lipoprotein-cholesterol (LDL-c) samples on seven POCT devices. All samples were representative of a clinically relevant concentration range for TC, HDL-c, and LDL-c. Accuracy was compared to reference values obtained by the CDC reference measurement procedures.ResultsThe mean bias for TC ranged among devices from -8.17% to 11.99% for whole blood and -7.89% to 7.02% for serum, respectively. The mean imprecision for TC in whole blood ranged from 1.94% to 11.63%, and in serum from 1.72% to 12.70%. The mean bias for serum HDL-c samples ranged from -7.33% to 17.36%, and for serum LDL-c samples from -20.92% to 5.04%. The mean imprecision for serum HDL-c samples ranged from 2.39% to 24.27% and for serum LDL-c samples ranged from 3.14% to 18.33%. For three of the eight devices, about 25% of the whole blood measurements and 50% of the serum measurements were reported outside of the measurement range and not included in the assessment. Comparing these non-reports with the reference values of these samples indicate that all of the reference values for whole blood and about 80% of the reference values for serum were actually within the measurement range of the device.ConclusionsThe technical assessment was helpful in building screening capacity in areas with limited laboratory infrastructure. The analytical assessment indicates notable differences in accuracy and precision for lipids measured in whole blood and serum, with serum measurements being more likely within performance requirements used by CDC's standardization programs. Additional studies to assess other devices and/or analytes, and future work to assist manufacturers improve the analytical performance of POCT devices are needed.

Diagnostic accuracy of Cardiochek® PA point-of-care testing (POCT) analyser with a 3-in-1 lipid panel for epidemiological surveys

A-338 Assessing the Technical and Analytical Performance of Point of Care Testing Devices for Blood Lipids Measurements

Smartphone-based point-of-care lipid blood test performance evaluation compared with a clinical diagnostic laboratory method

Comparison of Two Strategies for Hypercholesterolemia Detection through Point-of-Care Testing

Evaluation of the analytical and clinical performance of a high-sensitivity troponin I point-of-care assay in the Mersey Acute Coronary Syndrome Rule Out Study (MACROS-2)

A Photochemical Dongle for Point-of-care Evaluation of Blood Lipid Level

Review—Enzymatic Strips for Detection of Serum Total Cholesterol with Point-of-Care Testing (POCT) Devices: Current Status and Future Prospect

Comparison of Point-of-care Testing and Laboratory Testing of Myocardial Damage Markers in the Diagnosis and Prognosis of Acute Coronary Syndrome

Point-of-care testing of four chronic disease biomarkers in blood based on a low cost and low system complexity microfluidic chip with integrated oxygen-sensitive membrane

Point of Care Testing (POCT) of Cholesterol in Blood Serum Via a Moving Reaction Boundary Electrophoresis Titration Chip

Evaluation of a Novel Small Dense Low-Density Lipoprotein Cholesterol Kit and Investigate the Clinical Value in the Population of Coronary Heart Disease

Point-of-Care Testing for Multiple Cardiac Markers Based on a Snail-Shaped Microfluidic Chip

The Clinical Situation of Point-of-Care Testing and Its Future Development at the Emergency Department in Shanghai

Performance and usability of cardiometabolic point of care devices in Nepal: A prospective, quantitative, accuracy study

Assessment of novel POCT to evaluate liver function

The diagnostic value of echocardiography combined with serum Hcy and PCSK9 in coronary heart disease.

Clinical and Analytical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay

Cardiac biomarkers by point-of-care testing – back to the future?

Tracking the Risk of Cardiovascular Disease after Almond and Oat Milk Intervene or Statin Medication with a Powerful Reflex SH-SAW POCT Platform

Self-served and fully automated biochemical detection of finger-prick blood at home using a portable microfluidic analyzer

Rapid and Low-Cost CRP Measurement by Integrating a Paper-Based Microfluidic Immunoassay with Smartphone (Crp-Chip)